BioXcel Therapeutics, Inc. Forecast, price target & analysts
BioXcel Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
BioXcel Therapeutics, Inc. Classifications & Recommendation:
BioXcel Therapeutics, Inc. Price Target
| Target Price | $9.50 |
| Price | $1.56 |
| Potential |
508.97%
register free of charge
|
| Number of Estimates | 2 |
|
2 Analysts have issued a price target BioXcel Therapeutics, Inc. 2026 .
The average BioXcel Therapeutics, Inc. target price is $9.50.
This is
508.97%
register free of charge
$18.00
1,053.85%
register free of charge
$1.00
35.90%
register free of charge
|
|
| A rating was issued by 2 analysts: 1 Analysts recommend BioXcel Therapeutics, Inc. to buy, 0 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BioXcel Therapeutics, Inc. stock has an average upside potential 2026 of
508.97%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 2.27 | 1.68 |
| 64.49% | 26.15% | |
| EBITDA Margin | -2,841.41% | -2,769.47% |
| 76.56% | 2.53% | |
| Net Margin | -2,625.55% | -1,370.35% |
| 79.76% | 47.81% |
2 Analysts have issued a sales forecast BioXcel Therapeutics, Inc. 2025 . The average BioXcel Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an BioXcel Therapeutics, Inc. EBITDA forecast 2025. The average BioXcel Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 BioXcel Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average BioXcel Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -23.51 | -4.20 |
| 76.10% | 82.14% | |
| P/E | negative | |
| EV/Sales | 50.08 |
2 Analysts have issued a BioXcel Therapeutics, Inc. forecast for earnings per share. The average BioXcel Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
BioXcel Therapeutics, Inc....
Current BioXcel Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Rodman & Renshaw |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 30 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Jan 07 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jan 06 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 21 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 06 2024 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 30 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Rodman & Renshaw:
Locked
➜
Locked
|
Mar 19 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 30 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Jan 07 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jan 06 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 21 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 06 2024 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 30 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
